Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price

Key Points

• Guggenheim raised its Roivant Sciences price target to $42 from $36 and maintained a “buy” rating, implying 16.33% upside from the reported $36.10 share price.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and average price target of $34.77; HC Wainwright also raised its target to $41, while other firms maintained buy, neutral, or sell ratings.
• Roivant shares have risen substantially, trading near their 12-month high of $37.00, although insiders sold about 2.06 million shares worth $69.6 million in the last quarter.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) had its price target increased by equities researchers at Guggenheim from $36.00 to $42.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's target price suggests a potential upside of 16.33% from the company's current price.

A number of other research firms have also weighed in on ROIV. Weiss Ratings lowered shares of Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday, May 22nd. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research report on Thursday, May 21st. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a research note on Friday, July 31st. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a report on Thursday. Finally, HC Wainwright lifted their price target on shares of Roivant Sciences from $34.00 to $41.00 and gave the company a "buy" rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $34.77.

Roivant Sciences Price Performance

ROIV traded up $0.98 during trading on Friday, hitting $36.10. 2,747,517 shares of the stock traded hands, compared to its average volume of 5,919,824. The firm has a market capitalization of $25.97 billion, a P/E ratio of -60.14 and a beta of 1.12. The firm has a 50-day moving average of $33.00 and a 200 day moving average of $29.41. Roivant Sciences has a 12-month low of $10.90 and a 12-month high of $37.00.

Insider Activity

In related news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares in the company, valued at $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of the company's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director directly owned 16,474 shares in the company, valued at approximately $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,055,913 shares of company stock worth $69,639,633 in the last quarter. 8.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. SBI Securities Co. Ltd. boosted its stake in Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after acquiring an additional 1,166 shares in the last quarter. Allworth Financial LP increased its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after purchasing an additional 520 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $47,000. Finally, Bessemer Group Inc. boosted its position in shares of Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after purchasing an additional 441 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source